Respiratory Pathogen Panel

  • Qualitative multiplexed nucleic acid-based in vitro diagnostic test
  • Detect and differentiate 17 pathogens and subtypes from one sample, all-in-one test
Respiratory Pathogen Panel

The BioCode® Respiratory Pathogen Panel* is a qualitative multiplexed nucleic acid-based in vitro diagnostic test that is capable of the simultaneous detection and identification of nucleic acids from multiple viruses and bacteria extracted from nasopharyngeal swab (NPS) samples obtained from individuals with signs and/or symptoms of respiratory tract infection.

The BioCode® Respiratory Pathogen Panel can identify the following pathogens: 

Pathogen Detected
  • Adenovirus
  • Coronavirus (229E, OC43, HKU1, and NL63)
  • Human Metapneumovirus A/B
  • Influenza A, including subtypes H1, H1 2009 Pandemic, and H3
  • Influenza B
  • Parainfluenza 1
  • Parainfluenza 2
  • Parainfluenza 3
  • Parainfluenza 4
  • Respiratory Syncytial Virus A/B
  • Rhinovirus/Enterovirus
  • Bordetella pertussis
  • Chlamydia pneumoniae
  • Mycoplasma pneumoniae
Internal Control
  • MS2


Features and Benefits of the BioCode® Respiratory Pathogen Panel Assay


  • Delivers 188 patient samples in an 8-hour shift


  • Data Masking option enables select target reporting based on clinician’s order


  • Detect and identify 17 microbial pathogens and subtypes
  • Parallel testing with other FDA-cleared BioCode® assays
Respiratory Pathogen Panel

*The BioCode® Respiratory Pathogen Panel is US FDA 510(k) cleared in the US and CE Mark in Europe. The CE Mark for the BioCode® Respiratory Pathogen Panel includes all the targets listed except for Chlamydia pneumoniae.